CRISPR Therapeutics’ (CRSP) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $65.00 price target on the stock. A number of other research firms have also weighed in on CRSP. Chardan Capital dropped their price objective on […]
HC Wainwright reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $65.00 price target on the stock. A number of other research firms have also weighed in on CRSP. Chardan Capital dropped their price objective on […]
